Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Job research > Medical Statistics > Flashcards

Medical Statistics Flashcards

1
Q

P-value

A

probability of rejecting H0 with the value of the test statistic obtained from the data given H0 is true

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Confidence interval

A

measures the degree of uncertainty or certainty in sampling method, and is the range of plausible values for an unknown parameter (finding test statistic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Odds ratio

A

describes the strength of the association between two events, ad/bc

the ratio of the odds of A in the presence of B and the ratio of the odds of A in the absence of B. p1/1-p1 / p2/1-p2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Confounding

A

a variable that influences the independent and dependent variable (we want to eliminate this in a test) (true effect on X and Y is hidden by confounding variable c)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Interaction

A

relationship between three or more variables

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Z distribution and t distribution

A

z is when sample is large and variance is known, and t is when sample is small and variance is unknown

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Tables, figures and listings

A

how data is represented and analysed for clinical trials with SAS (type of software they use in pharmaceutical companies, especially when considering clinical trials)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Efficacy

A

the effect in ‘perfect conditions’

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Effectiveness

A

the effect in real world conditions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Crossover trial

A

when subjects receive a sequence of different treatments, but the order they receive them might be randomised

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

ANCOVA

A

analysis of covariance, comparing one variable in two or more populations while considering other variables (ANOVA doesn’t consider other variables)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

End points

A

outcomes measures referring to occurrence of disease, symptom, sign, or laboratory abnormality constituting a target outcomes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Equivalence trial

A

statistical test which aims at showing that two treatments are not different in characteristics (so not too different)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Non-inferiority trial

A

demonstrates that the test product in not worse than the competitor by more than a pre-specified amount (so is significantly better than the other)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Block randomisation

A

randomising patients in blocks such that an equal number are assigned to each treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Stratification

A

partitioning of subjects and results in a way other than the treatment given

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Drop-out

A

when patients leave the trial prematurely

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Power

A

probability of avoiding a type 2 error (when the type 2 error is to accept a false hypothesis), (1 - p(type 11 error)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Classification

A

by purpose or by phase in drug development

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Phase I

A 
focus upon the Pharmacokinetics/Pharmacodynamics
(absorption, distribution, metabolism
and excretion of a drug or vaccine)
and toxicity (drug safety); Maximum
Tolerated Dose (MTD)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Phase II

A

initial clinical investigation into doses and dose schedules, (dosefinding,) and early indications of efficacy
(e.g. dose-finding study)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Phase III

A

aimed at full scale evaluation, efficacy, of a new, experimental, treatment compared to a standard
therapy or placebo, acting as a control

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Phase IV

A

effectiveness, post marketing
surveillance (information re: uncommon
side effects, long-term effects)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Effect

A

difference between what happened
to the patient as a result of treatment and
what would have happened if treatment had
been denied’

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Efficiency

A

the economics of treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

International Guidelines

A

Guidelines for Good Clinical Practice, particularly for

assessing safety and efficacy of medicinal products

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Trialists objectives

A

minimise bias and maximise efficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Key design issues include:

A

replication, control, randomisation, blocking, treatment blinding/ masking, ethics, choice of analysis set,

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

aim

A

to yield treatment groups which are indeed

comparable in terms of extraneous factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Block Randomisation

A

balance numbers of participants in each

group

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Stratified Randomisation

A

use block randomisation in each stratum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Adaptive randomisation: Minimisation

A

use simple randomisation when
groups are balanced: when imbalanced allocate
next patient to treatment so that imbalance is
minimised (via minimisation score)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Treatment Blinding: single blind

A

patient does not know which

treatment is being received

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Treatment Blinding: double-blind

A

neither patient nor physician knows the treatment allocation (GoldStandard)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Treatment Blinding: triple-blind

A

as double-blind also the monitoring group and data analyst do not know which
group receives experimental and which control
treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Treatment Blinding: open

A

all are knowledgeable about the treatment allocation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

placebo

A

dummy copy of treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

double-dummy

A

method for comparison of 2
active treatments with different appearance (ie two treatments which is in two different forms, drug A and drug B, with placebo A and placebo B)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Central Limit Theorem

A

when independent random variables are added, their properly normalized sum tends toward a normal distribution even if the original variables themselves are not normally distributed

40
Q

risk difference

A

RD = a/(a + c) - b/(b + d)

I think it’s the additional risk of taking the drug over not taking it

41
Q

relative risk

A

RR = (a/(a + c))/(b/(b + d))

the ratio of the probability of an outcome in an exposed group to the probability of an outcome in an unexposed group

42
Q

parallel group design

A

different groups of
patients are studied concurrently (in parallel).
Patients receive a single therapy (or combination
of therapies) −→ estimate of treatment effect is
based upon so-called ’between-subject’ comparisons. We used the two independent samples
t-test for inference

43
Q

paired design

A

patient receives both treatment
for example, matching parts of anatomy (e.g.
limbs, eyes, kin etc) −→ estimate of treatment
effect is based upon ’within-subject’ comparison.
We used a paired t-test (one sample t-test
on the within subject differences). We noted
asymmetry can be problematic

44
Q

wash-out period

A

A wash-out period is a period in a trial during
which the effect of a treatment given previously is believed to disappear. If no treatment
is given during the wash-out period then the
wash-out is passive. If a treatment is given
during the wash-out period than the wash-out
is active

45
Q

Epidemiology

A

study of the distribution

and determinants of disease in human populations.

46
Q

target population

A

population about we wish to draw inferences for

47
Q

study population

A

population from which data are collected

48
Q

generalisability

A

can we use the study population results to draw accurate conclusions about the target?

49
Q

incidence

A

number of new cases of the disease within a specified period of time

50
Q

prevalence

A

number of existing cases of the disease at a particular point in time,
P = (number of people with the disease at a specified time t)/(number in the population at risk at the specified time t)

51
Q

incidence rate

A

I = (number of people who develop disease in a specified time period)/(sum of the length of time during which each person in the population is at risk)

52
Q

cumulative incidence risk

A

CI = (Number of people who get a disease during a specified period)/(Number of people free of the disease at the beginning of the period)

53
Q

crude mortality rate

A

number of deaths in a specified period of time, divided by the average population at risk during that period
multiplied by the length (years) of the study
period (person-years)

54
Q

sensitivity

A

the proportion of truly diseased persons
in the tested population who are identified as diseased by the screening test (probability of diagnosing a true case as diseased)
P(Truly diseased given Diseased)

55
Q

specificity

A

the proportion of truly non-diseased persons who are so identified by the screening test
(probability of diagnosing a truly non-diseased
person as non-diseased):
P(Truly not diseased given non diseased

56
Q

positive predictive value

A

is the proportion of persons who are in fact diseased among those who test positive

57
Q

negative predictive value

A

the proportion of persons who are in fact non-diseased among those
who test negative

58
Q

receiver operating characteristic

A

sensitivity, specificity and their sum can be plotted to
evaluate the various cut-points but typically a plot
of sensitivity against (1 - specificity) is produced
for the various cutoff values

59
Q

likelihood ratio

A

sensitivity/(1 - specificty)

60
Q

observational studies

A

in which the investigators role is passive in that exposures are not manipulated

61
Q

intervention studies

A

in which the investigators
role is active: groups are exposed to interventions
of interest such as treatments. These are experimental studies: clinical trials

62
Q

cross-sectional studies

A

surveys also feature but since they provide information at a snap-shot in time (both exposure and disease) they are less useful and can only be used to measure disease prevalence

63
Q

Cohort Studies

A

A cohort study tracks two or more groups

forward from exposure to outcome

64
Q

Case-Control Studies

A

case and control groups defined and selected
according to their disease status: diseased /
non-diseased (outcome to exposure)

65
Q

matching

A

selecting controls to be similar to
cases in terms of confounders (e.g. age, gender,
smoking habits)

66
Q

stratification

A

examine exposure-disease associations within strata (e.g age groups, smoking groups) and estimate pooled estimate of association measure adjusting for confounding effect

67
Q

standardisation

A

controlling confounding using an external population to adjust for age, gender etc yielding standardised rates

68
Q

multivariate analysis/regression models

A

include confounding variable in the model (model

adjustment

69
Q

Standardisation

A

to compare the incidence of disease or mortality between two or more populations

70
Q

direct standardisation

A

the disease rates in the population of interest are applied to the standard population counts

71
Q

indirect standardisation

A

the disease rates in the standard population are applied to the population of interest

72
Q

direct standardised event rate

A

the expected event rate in the ’standard’ population if the age-specific event rates in the study population
prevailed

73
Q

survival analysis

A

analysis of data in the form of times from some well-defined time origin to occurrence of some event or endpoint”

74
Q

3 types of Survival Analysis

A

Positive (such as discharge from hospital or time
to conception)
Adverse (such as death or recurrence of disease)
Neutral (such as cessation of breast feeding)

75
Q

Right Censoring

A

the event time exceeds the last follow-up time

76
Q

Left Censoring

A

the event time precedes the last follow-up time but is unknown

77
Q

survivor function

A

the survival time of individual i

78
Q

hazard function

A

a realisation of a non-negative random variable T

79
Q

empirical survivor function

A

S = (number of individuals with survival times > t) / (total number of participants)

80
Q

Type 1 error

A

h0 is rejected but h0 true

81
Q

Type 2 error

A

h0 is accepted but h0 false

82
Q

Mantel-Haenszel Method

A

technique that generates an estimate of an association between an exposure and an outcome after adjusting for or taking into account confounding

83
Q

Hazard function

A

f(x)/ 1 – F(x)

84
Q

Kaplan-Meier function

A

The Kaplan Meier Curve is an estimator used to estimate the survival function. The Kaplan Meier Curve is the visual representation of this function that shows the probability of an event at a respective time interval

85
Q

Survival analysis

A

analyzing the expected duration of time until one or more events happen, such as death in biological organisms and failure in mechanical systems.

86
Q

Non parametric models

A

Non-parametric models assume that the data distribution cannot be defined in terms of such a finite set of parameters. But they can often be defined by assuming an infinite dimensional θ.

87
Q

Logisitic regression

A

like linear models but for discrete data

88
Q

Case control study

A

type of observational study in which two existing groups differing in outcome are identified and compared on the basis of some supposed causal attribute. (outcome to exposure)

89
Q

Cohort study

A

exposure to outcome: Conducting a study by selecting groups, then waiting a period of time before comparing the groups ie after initial exposure we then pick the groups and wait for outcome

90
Q

type of test to use when input is nominal and output is normal

A

t test

91
Q

type of test to use when input is continuous and output is nominal

A

logisitic regression

92
Q

test which tests if there is an association between two variables

A

Chi squared test

93
Q

Period Effect

A

Period effects may arise where patients may do better in a subsequent period because their state has changed, for example, their mental or health status has changed, independent of treatment.

94
Q

Carry over

A

If the effect of a treatment carries on after the treatment is withdrawn then the response to a second treatment may well be due in part to the previous treatment

95
Q

Gold standard

A

In medicine and statistics, a gold standard test is usually the diagnostic test or benchmark that is the best available under reasonable conditions. Other times, a gold standard is the most accurate test possible without restrictions.

96
Q

Receiver operating characteristic

A

a graphical plot that illustrates the diagnostic ability of a binary classifier system as its discrimination threshold is varied

Job research (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions